中国中免：前三季度净利润同比下降22.13%

Core Viewpoint - China National Medicines Corporation (601888.SH) reported a decline in both revenue and net profit for the third quarter of 2025, indicating potential challenges in the company's financial performance [2]. Financial Performance - In Q3 2025, the company achieved a revenue of 11.711 billion yuan, a year-on-year decrease of 0.38% [2]. - The net profit attributable to shareholders for Q3 2025 was 452 million yuan, down 28.94% year-on-year [2]. - For the first three quarters of 2025, the total revenue was 39.862 billion yuan, reflecting a year-on-year decline of 7.34% [2]. - The net profit attributable to shareholders for the first three quarters was 30.520 billion yuan, which represents a year-on-year decrease of 22.13% [2].